Pharmerging Market (By Product: Pharmaceuticals, Healthcare; By Indication: Lifestyle Diseases, Cancer and Autoimmune Diseases, Infectious Diseases, Others; By Economy: Tier-1, Tier-2, Tier-3; By Distribution Channel: Hospitals, online Stores, Retail Pharmacies, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2033

The global pharmerging market size was valued at USD 1.73 trillion in 2023 and it is expected to surpass around USD 3.99 trillion by 2033, growing at a registered CAGR of 8.72% from 2024 to 2033.

Pharmerging Market Size 2024 to 2033

To Access our Exclusive Data Intelligence Tool with 15000+ Database, Visit: Precedence Statistics

Key Takeaways

  • Asia Pacific led the global market with the highest market share of 62.15% in 2023.
  • By products, the pharmaceutical segment registered a maximum market share of 71.70% in 2023.
  • By economy, the tier 1 segment has held the largest market share in 2023.
  • By distribution channel, the online store segment registered the maximum market share in 2023.

Pharmerging Market Size in the Asia Pacific  2024 To 2033

The Asia Pacific pharmerging market size reached USD 1.08 billion in 2023 and is anticipated to be worth around USD 2.54 billion by 2033, poised to grow at a CAGR of 8.97% from 2024 to 2033.

Asia Pacific Pharmerging Market Size 2024 to 2033

The basis of geography the Asia Pacific market is expected to have the largest market share 62.15% the reasons for the Asia Pacific market to have a dominating position is due to the increasing patent expiration, increased urbanization and a spike in the medical research investments by various governments. It is estimated that the Asia Pacific market will remain on top. In the Asia Pacific market China dominates this region. China has the potential to grow exponentially during the forecast. Increased penetration of insurance policies and the entry of major companies into new markets with wide variety of product portfolio is expected to boost the market in the Asia Pacific region. Asia Pacific market revenue was valued at USD 1.08 trillion in 2023.

In the United States there'll be a major pressure due to the prices which will intensify. In order to make up for the loss during the pandemic the commercial insurance providers and the hill systems are seeking ways to make for it. Among the other regional markets the Latin America and the European market is also likely to witness healthy growth in the near future for the pharmerging market. Increasing awareness regarding the treatment, management of health care facilities, extensive research and development and technological advancements are propelling the growth of the Latin American market. Due to the large population size and increasing prevalence of various diseases the European market is expected to have a good growth during the forecast. The Middle East and the African region are also expected to have a small share of the global far merging market in the forecast period.

Pharmerging Market Share, By Region, 2023 (%)

Market Overview

Pharmerging combines two words pharma and emerging. Pharma refers to the Pharmaceutical industry and emerging means the upcoming markets. The prescription and the over the counter drugs are taken in account. Heart diseases, diabetes, respiratory disorders and cancer are the variety of diseases that are covered under this industry. Pharmerging is a combination of countries that have a low positioning in the pharmaceutical market, but they have a speedy growth. India, China, South Africa, Brazil, Russia, Indonesia and Turkey are some of the key pharmerging markets. Pharmerging is a term which is used to describe a collection of countries which have a poor position in the pharmaceutical sector but they are expanding rapidly. The farming market has benefited well due to the non-communicable diseases which ever increased across various nations and the life expectancy. As there is an increase in the global pharmaceutical business there shall be increased collaborations acquisition there shall be international mergers and also increase in public as well as the private healthcare insurances. The global farming market it's constrained as there is an increase in research and development costs and it also involves a regulatory clearance process which is extremely lengthy. The market expansion is also limited as the remedy concerns with the IP protection and issues that are sociopolitical.

 The global farming industry was already suffering due to the slower price rises increasing costs and declining R&D productivity. The pandemic challenged the industry even more Due to its effects on the health care system and the uncertainty of the vaccination supply. All the industries have suffered a setback during pandemic. Due to the restrictions and lockdown imposed by government across the world lead to a disruption in the manufacturing and the supply chain operations. This economic situation affected the demand as people started concentrating more on the essential expenses and budgets.

Growth Factors

The increasing expenditure on healthcare industry and the increase of private hospitals are leading the growth of the global farming market. The prevailing chronic diseases amongst the consumers and the growing consumer awareness for early disease detection and treatment procedures are leading to a growth in this market. The geriatric population in many countries is extremely prone to some serious medical conditions like cardiac failure, dementia and hypertension. These age-related conditions are creating a demand for pharmaceuticals. There are many reimbursement schemes which are provided by various countries in order to reduce the cost of treatment for such chronic diseases and also there is an introduction of policies by various governments which help in the growth of the market. These chronic diseases require a constant and prolonged treatment. A general awareness regarding the insurance policies for health care and growing number of insurance companies in the farmers in countries is offering insurance policies to decrease the out-of-pocket expenditure in these countries and there is an increased demand for pharmaceuticals in this country. Apart from the chronic disorder that help in the growth of the market there are increased investments in the extensive research and development activities in various fields of these countries. Advanced treatments are introduced in the fields of biotechnology, oncology and immunology and it is helping in the growth of the market.

The pace of various diseases is increasing and as a result, concern regarding the innovative and higher quality results is burgeoning. This factor will possibly fetch a significant advancement of this market in the time to come. The continuous advancement and progress in the medicine for the therapeutics of a huge group of illnesses are anticipated to boost pharmerging market over the next few years.

The global market is meeting a crucial launch, primarily in the developing countries worldwide. The growing prevalence of non-communicable ailments, sprouting population, enlarging future, hiking pay, swamping expenditure of the government on medical treatment, global partnerships, and the continuous inventive work are a part of influential components at the back of the advancement of this market.

Pharmerging Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 8.72%
Market Size in 2023 USD 1.73 Trillion
Market Size by 2033 USD 3.99 Trillion
Asia Pacific Market Share in 2023 62.15%
Pharmaceutical Segment Market Share in 2023 71.70%
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Product, By Indication, By Economy, and By Distribution Channel
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa


Products Insights

There are two products considered in this segment, which are pharmaceuticals and other healthcare products. The pharmaceutical segment holds the larger market share 71.70% in 2023. The pharmaceutical segment includes over the counter drugs generic prescription drugs. Patented prescriptions drugs during the forecast period, the generic prescription drugs are estimated to have the largest market share. The generic prescription drug segment shall increase the growth of the pharmaceutical industry in the coming years. As the nations are price sensitive and the expenditure is made out of pocket. These factors are expected to boost the generic prescription drugs market in such countries.

Pharmerging Market Share, By Product, 2023 (%)

The increasing number of various innovative therapies for treatment of diseases at an affordable price shall also boost the segment in the coming years. There is a growing emphasis on the medical devices which are used for the treatment and the diagnosis of various diseases. The other healthcare verticals include clinical diagnostics and medical devices.

The healthcare segment accounted revenue share of around 28.30% in 2023.

Economy Insights

Tier 1 segment is anticipated to be the highest in between all the pharmerging nations in the years to come and is predicted to continue its dominance during the forecast timeframe. The healthcare market in the Tier 1 economy is augmenting the growth of this market across the globe. In the Tier 2 segment, India will exhibit the fastest growth in the time to come. Tier 2 economy also has an inclusion of countries like South Africa and Russia.

Tier 3 economy consists of various nations such as Ukraine, Egypt, Thailand, Mexico, Saudi Arabia, Indonesia, Algeria, Turkey, Pakistan, Poland, Nigeria, among others. Tier economy segment is expected to grow at a steady pace over the period of time. The healthcare market is primarily growing in the Tier 3 economies of Nigeria, Thailand, and Indonesia, and these countries are expected to grow at a faster rate of the pharmeging market in the years to come.

Distribution Channel Insights

Based on the distribution channel the online store segment is expected to have the largest market share during the forecast. Followed by the online stores the hospital segment is also expected to have a good sales volume during the forecast. In the next few years the online market segment will grow is there of any reimbursement schemes provided by governments and there is a reduction in the cost of chronic disease treatments and the investments for research and development and biotechnology cancer and immunology all of this will fuel the market expansion.

Key Market Developments

  • China medical system holdings and AstraZeneca signed a licensing agreement in 2016 in order to have global rights for the calcium channel blocker in China.
  • GSK's cervarix human papilloma virus was approved by the China Food and Drug administration. This approval will help in the treatment of the cervical cancer. China Food and Drug administration approved it in July 2016

Competitive Landscape

The global market of pharmerging is witnessing an indisputable level of competition in between the top players. The operation of large store of players has piled the vendor spot divided, and at the same time, constant citation of new players entering the market is reckoning the submerging are of competition within this market in particular. They will shift their focus in the direction of unexposed business industries with feasible liberty over the next decade. They are multitudinously predicted to involve much more into necessary harmonized endeavors which is going to fuel the market development exceedingly.

Pharmerging Market Companies

  • Sanofi S.A.
  • Pfizer Inc.
  • AstraZeneca Plc
  • GlaxoSmithKline Plc
  • F. Hoffmann-La Roche AG (Roche AG)
  • Novartis AG
  • Teva Pharmaceutical Limited.
  • Eli Lilly and Company
  • Johnson & Johnson Corporation
  • Abbott Laboratories

Segments covered in the report

By Product

  • Pharmaceuticals
    • Patented Prescription Drugs
    • Generic Prescription Drugs
    • OTC Drugs
  • Healthcare
    • Medical Devices
    • Clinical Diagnosis
    • Others

By Indication

  • Lifestyle Diseases
  • Cancer and Autoimmune Diseases
  • Infectious Diseases
  • Others

By Economy

  • Tier-1
  • Tier-2
  • Tier-3

By Distribution Channel

  • Hospitals
  • online stores
  • retail pharmacies
  • others

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions

What is the current size of pharmerging market?
The global pharmerging market size was reached at USD 1.73 trillion in 2023 and it is anticipated to hit around USD 3.99 trillion by 2033.
What will be the CAGR of global pharmerging market?
The global pharmerging market is expected to drive growth at a CAGR of 8.72% from 2024 to 2033.
Who are the major players operating in the pharmerging market?
The major players operating in the pharmerging market are Sanofi S.A., Pfizer Inc., AstraZeneca Plc, GlaxoSmithKline Plc, F. Hoffmann-La Roche AG (Roche AG), Novartis AG, Teva Pharmaceutical Limited., Eli Lilly and Company, Johnson & Johnson Corporation, and Abbott Laboratories.
Which are the driving factors of the pharmerging market?
The Pharmerging market is a growing market in developing and under developed countries which deals with pharmaceutical companies.
Which region will lead the global pharmerging market?
Asia Pacific region will lead the global pharmerging market over the forecast period 2024 to 2033.


   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500


No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Get a Sample